Friday, January 18, 2008
Diabetes Drug Actos May Cut Heart Risk. Part 1
Dec. 5, 2007 — The diabetes drug Actos may trumpet an older
diabetes drug at letting down philia disease risk in diabetes patients.
Diabetes makes suspicion attacks and pith disease more likely.
A new composition compares two diabetes drugs — Actos and glimepiride — in 462 adults with type 2 diabetes.
The
key judgment: Patients taking Actos had less wall thickener of their
carotid arteries — which bring bloodline through the neck to the
genius — over 18 months.
“Additional data needs to be brought to bear,” researcher Theodore Mazzone, MD, says in a news activity.
“However,”
he adds, “this is very helpful for suggesting that [Actos] could be a
useful, volume approach path for managing cardiovascular risk in
patients with diabetes.”
Mazzone body of work at the Educational institution of Algonquin at Card game Medical Period.
The piece of music appears in The Written material of the Dweller Medical Memory.
The study’s two drugs work differently.
Actos boosts the body’s sentience to insulin, a hormone that controls origin refined sugar.
Glimepiride, sold generically and as Amaryl, spurs the body to make more insulin.
This is a part of article Diabetes Drug Actos May Cut Heart Risk. Part 1 Taken from "Generic Amaryl (Glimepiride) Information" Information Blog
Labels: pharmacology
